Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
OBJECTIVE
To compare the efficacy of cabergoline (Cb2) and meloxicam in curbing vascular endothelial growth factor (VEGF) expression and preventing ovarian hyperstimulation syndrome (OHSS).


METHODS
Randomized controlled, animal study.


METHODS
Academic facility.


METHODS
We used a total of 50 immature Wistar female rats randomly to create an experimental OHSS model.


METHODS
Ten rats each formed the control group and mild OHSS group. The remaining 30 were separated into three equal groups of severe OHSS. Mild and severe OHSS were induced through ovarian stimulation with gonadotropins. One group with severe OHSS was administered a low-dose 100 microg/kg Cb2 therapy; another group with severe OHSS received 600 microg/kg meloxicam. Body weight, vascular permeability (VP), VEGF expression, ovary weight, and diameter were then compared.


METHODS
The efficacy of Cb2 and meloxicam for preventing OHSS.


RESULTS
Comparison of the severe OHSS groups with the controls and mild OHSS group revealed significant increases in VEGF expression, VP, ovary weight, and diameter. The increase in VEGF expression was demonstrated to be dependent on human chorionic gonadotropin doses. However, low-dose Cb2 and meloxicam therapies were shown to be ineffective in decreasing VEGF expression and VP, ovary weight, and ovary diameter in severe OHSS.


CONCLUSIONS
VEGF elevation played a critical part in OHSS pathogenesis, but the therapies administered failed to curb VEGF expression.
Saylan
Arif
A
Department of Obstetrics and Gynecology, Faculty of Medicine, Afyonkarahisar Kocatepe University, Afyonkarahisar, Turkey.
Arioz
Dagistan Tolga
DT
Koken
Tulay
T
Dilek
Husniye
H
Saylan
Filiz
F
Yilmazer
Mehmet
M
D000704:Analysis of Variance; D000818:Animals; D001707:Biopsy, Needle; D001835:Body Weight; D000077465:Cabergoline; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D007150:Immunohistochemistry; D007273:Injections, Intramuscular; D000077239:Meloxicam; D009929:Organ Size; D016471:Ovarian Hyperstimulation Syndrome / Q000473:pathology / Q000517:prevention & control*; D010053:Ovary / Q000187:drug effects* / Q000473:pathology; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods; D011247:Pregnancy; D011270:Pregnancy, Animal; D011336:Probability; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013843:Thiazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis
D006063:Chorionic Gonadotropin; D004873:Ergolines; D013843:Thiazines; D013844:Thiazoles; D042461:Vascular Endothelial Growth Factor A; D000077465:Cabergoline; D000077239:Meloxicam